Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance
-
摘要: 目的检测microRNA-222(miRNA-222)在肝细胞癌(HCC)组织中的表达,并探讨其临床意义。方法收集2012年1月-2014年12月于大连市中心医院、大连医科大学附属第一医院手术切除的HCC组织103例,采用实时定量PCR方法检测HCC、近癌旁肝硬化组织及远癌旁肝组织中miRNA-222的表达水平,分析miRNA-222表达与HCC临床病理特征之间的关系。计量资料多组间比较采用单因素方差分析,进一步两两比较采用Dunnett’s T3法;两组间比较采用t检验。结果 miRNA-222在HCC、近癌旁肝硬化组织及远癌旁肝组织中的表达差异有统计学意义(F=27.167,P<0.001),其在HCC组织中的相对表达量(4.543±2.029)明显高于在近癌旁肝硬化组织(3.072±0.844)及远癌旁肝组织(1.559±0.695)中的相对表达量(P值均<0.01);近癌旁肝硬化组织中miRNA-222的相对表达量显著高于远癌旁肝组织(P<0.01)。miRNA-222的表达与HCC的大小、分化程度、门静脉瘤栓、侵袭转移均有关联(t值分别为7.256、9.90...Abstract: Objective To investigate the expression of microRNA-222 ( miRNA-222) in hepatocellular carcinoma ( HCC) tissue and its clinical significance. Methods A total of 103 HCC tissue samples were collected from the patients who underwent surgical resection in Dalian Central Hospital and The First Affiliated Hospital of Dalian Medical University from January 2012 to December 2014. Quantitative real-time PCR was used to measure the expression of miRNA-222 in HCC tissues, adjacent cirrhotic tissues, and distal liver tissues, and the association between miRNA-222 expression and the clinicopathological features of HCC was analyzed. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Dunnett's T3 test was used for further comparison between any two groups; the t-test was used for comparison between two groups. Results There was a significant difference in the expression of miRNA-222 between HCC tissues, adjacent cirrhotic tissues, and distal liver tissues ( F = 27. 167, P < 0. 001) ; the HCC tissues had significantly higher relative expression of miRNA-222 than the adjacent cirrhotic tissues ( 4. 543 ± 2. 029 vs 3. 072 ± 0. 844, P < 0. 01) and the distal liver tissues ( 4. 543 ± 2. 029 vs 1. 559 ± 0. 695, P < 0. 01) , and the adjacent cirrhotic tissues had significantly higher relative expression of miRNA-222 than the distal liver tissues ( P < 0. 01) . The expression of miRNA-222 was significantly associated with tumor size, degree of tumor differentiation, tumor thrombus in the portal vein, and invasion/metastasis ( t = 7. 256, 9. 900, 2. 345, and 4. 225, all P < 0. 05) , while it was not associated with sex, age, the presence of viral hepatitis, or increased alpha-fetoprotein level ( all P > 0. 05) . Conclusion The expression of miRNA-222 is abnormally upregulated in HCC tissue, and miRNA-222 measurement may help to evaluate the clinical progression and prognosis of HCC.
-
Key words:
- carcinoma, hepatocellular /
- microRNAs
-
[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132. [2]BARTEL DP.MicroRNAs:genomics, biogenesis, mechanism, and function[J].Cell, 2004, 116 (2) :281-297. [3]FU Z, QIAN F, YANG X, et al.Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer[J].Med Oncol, 2014, 31 (9) :164. [4]LIU S, SUN X, WANG M, et al.A microRNA 221-and 222-mediated feedback loop maintains constitutive activation of NF-κB and STAT3 in colorectal cancer cells[J].Gastroenterology, 2014, 147 (4) :847-859. [5]ZHANG DQ, ZHOU CK, JIANG XW, et al.Increased expression of miR-222 is associated with poor prognosis in bladder cancer[J].World J Surg Oncol, 2014, 12:241. [6]XU L, MA KX, DONG B, et al.Regulatory effect of miRNAs on apoptosis, migration, and cell cycle of hepatocellular carcinoma cells[J].J Clin Hepatol, 2013, 29 (7) :554-557. (in Chinese) 许力, 马珂歆, 董兵, 等.肝细胞癌中microRNA对细胞凋亡、转移和周期的调控作用[J].临床肝胆病杂志, 2013, 29 (7) :554-557. [7]MIRZAEI HR, SAHEBKAR A, MOHAMMADI M, et al.Circulating microRNAs in hepatocellular carcinoma:potential diagnostic and prognostic biomarkers[J].Curr Pharm Des, 2016, 22 (34) :5257-5269. [8]DENG X, WU JB.Updates in the research of relationship between MicroRNAs and hepatocellular carcinoma[J].Chin J Dig Surg, 2015, 14 (5) :431-433. (in Chinese) 邓曦, 吴敬波.微RNAs与肝癌关系的研究进展[J].中华消化外科杂志, 2015, 14 (5) :431-433. [9]WONG QW, CHING AK, CHAN AW, et al.MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling[J].Clin Cancer Res, 2010, 16 (3) :867-875. [10]KARAKATSANIS A, PAPACONSTANTINOU I, GAZOULI M, et al.Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance[J].Mol Carcinog, 2013, 52 (4) :297-303. [11]ZHANG ZZ, LIU X, WANG DQ, et al.Hepatitis B virus and hepatocellular carcinoma at the miRNA level[J].World J Gastroenterol, 2011, 17 (28) :3353-3358. [12]FIORINO S, BACCHI-REQQIANI ML, VISANI M, et al.MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B-and C-related-hepatocellular-carcinoma[J].World J Gastroenterol, 2016, 22 (15) :3907-3936. [13] MURAKAMI Y, YASUDA T, SAIGO K, et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene, 2006, 25 (17) :2537-2545. [14]QI P, CHENG SQ, WANG H, et al.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection[J].PLo S One, 2011, 6 (12) :e28486. [15]ZHANG Y, YAO J, HUAN L, et al.GNAI3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR-222 in hepatocellular carcinoma[J].Cancer Lett, 2015, 356 (2Pt B) :978-984. [16]GAROFALO M, DI LEVA G, ROMANO G, et al.miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation[J].Cancer Cell, 2009, 16 (6) :498-509. [17]TAO XC, MA DL, WU DQ.Effect of up-regulating miR-222 in Hep G2 cells on its invasion and proliferation[J].Pract Oncol J, 2015, 29 (3) :235-238. (in Chinese) 陶宣辰, 马东来, 吴德全.上调miR-222对肝癌细胞系Hep G2增殖和侵袭能力的影响[J].实用肿瘤学杂志, 2015, 29 (3) :235-238. [18]JIANG F, ZHAO W, ZHOU L, et al.MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin[J].Int J Mol Sci, 2014, 15 (12) :22128-22141. [19]SHEN H, WANG D, LI L, et al.MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway[J].Gene, 2017, 596:110-118. [20]LIU K, LIU S, ZHANG W, et al.miR 222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma[J].Int J Oncol, 2014, 45 (4) :1537-1546.
本文二维码
计量
- 文章访问数: 2066
- HTML全文浏览量: 16
- PDF下载量: 378
- 被引次数: 0